Prakt. lékáren. 2010; 6(1): 6-8
Exenatide
- III. interní klinika UK 1. LF a VFN, Praha
Therapy using incretin analogues changes the treatment possibilities in type 2 diabetes in a large extent. Exenatide is the first clinically
used drug of this group. It is applied in subcutaneous injections twice daily. No hypoglycemic events are present and initial reports have
been published about the use of exenatide in nondiabetic obese patients to reduce weight. The secretion of glucagon is modulated and
the secretion of insulin is stimulated. The two main effects of exenatide are compensation of diabetes and weight reduction. There are
also other effects: improvement of dyslipidemia and blood pressure reduction. Prescription is limited to the oral antidiabetic drug failure
must be documented. In patients with a BMI over 35, only a very small payment by the patient is necessary. Currently, exenatide is given
in combination with other oral antidiabetic drugs, especially metformin. According to the studies already conducted, monotherapy
shortly after the diagnosis of type 2 diabetes might be possible in the future.
Keywords: incretin analogues, type 2 diabetes, obesity
Published: March 1, 2010 Show citation
References
- Svačina Š. Potenciální nová antidiabetika pro příští desetiletí. Vnitř Lék. 2009; 55(4): 429-433.
Go to PubMed... - Svačina Š, Doležal T. Exenatid. Farmakoterapie. 2008; 4(3): 291-295.
- Keating GM. Exenatide. Drugs. 2005; 65(12): 1681-1692.
Go to original source... Go to PubMed... - Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001; 50(5): 583-589. Go to original source... Go to PubMed...
- Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90(11): 5991-5997. Go to original source... Go to PubMed...
- Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004; 53(9): 2397-2403. Go to original source... Go to PubMed...
- Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281(1): E155-E161. Go to original source... Go to PubMed...
- Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8(4): 436-447. Go to original source... Go to PubMed...
- Hiles R, Carpenter T, Serota D. Exenatide does not cause pancreatic islet cell proliferative lesions in rats and mice following 2-Pears exposure. Diabetes 2004; 53(Suppl. 2): A380.
- Svačina Š. Antidiabetika a krevní tlak. In: Widimský J, a kol. Arteriální hypertenze současné trendy - VII. symposium. 1. vydání. Praha: Triton, 2009: 150 s.
- Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005; 7(3): 467-477. Go to original source... Go to PubMed...
- Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Diabetes Care. 2004; 27(11): 2628-2635.
- Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007; 29(11): 2333-2348. Go to original source... Go to PubMed...
- Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5): 1083-1091. Go to original source... Go to PubMed...
- Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24(1): 275-286. Go to original source... Go to PubMed...
- Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143(8): 559-569. Go to original source... Go to PubMed...
- Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a longacting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30(6): 1487-1493. Go to original source... Go to PubMed...
- ##
- Rybka J. Sitagliptin - představitel inkretinové léčby diabetu 2. typu. Praktické lékárenství 2009; 5(4), 159-162.
- Kwak HH, Shim WS, Hwang S, et al. Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats. Pharmaceutical Research 2009; 26(11): 2504-2512. Go to original source... Go to PubMed...
- Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-1705. Go to original source... Go to PubMed...